Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been assigned a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $56.00.

Several analysts have recently weighed in on TARS shares. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Barclays raised their price target on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. Finally, Guggenheim restated a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently made changes to their positions in TARS. Prudential Financial Inc. increased its stake in shares of Tarsus Pharmaceuticals by 43.7% in the 4th quarter. Prudential Financial Inc. now owns 148,735 shares of the company’s stock worth $8,235,000 after acquiring an additional 45,240 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in Tarsus Pharmaceuticals in the 4th quarter valued at about $25,000. Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company’s stock valued at $117,117,000 after buying an additional 17,839 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at approximately $299,000. Finally, Sei Investments Co. grew its position in Tarsus Pharmaceuticals by 35.8% in the fourth quarter. Sei Investments Co. now owns 48,180 shares of the company’s stock worth $2,668,000 after acquiring an additional 12,689 shares during the period. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $51.22 on Wednesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -13.44 and a beta of 1.01. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a fifty day moving average of $52.05 and a 200 day moving average of $41.22.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.